Literature DB >> 23270655

Benefits of continuous subcutaneous insulin infusion on quality of life.

Andrea Lukács1, Emőke Kiss-Tóth, Beatrix Varga, Andrea Soós, Peter Takác, László Barkai.   

Abstract

PURPOSE: The aim of this study was to compare the general health-related quality of life (HRQoL), the metabolic control (HbA1c), the anthropometric measurement, and the cardiorespiratory fitness (expressed by VO2max) in youths with type 1 diabetes treated with continuous subcutaneous insulin infusion (CSII) to those receiving multiple daily injections (MDI). We looked for factors influencing the HRQoL and metabolic control.
METHODS: A total of 239 patients treated with CSII (51 girls and 53 boys) or MDI (64 girls and 71 boys) between ages 8 and 18 years were assessed with the Pediatric Quality of Life Inventory, Generic Core Scales, and Diabetes Module. VO2max was evaluated using the 20-meter shuttle run test.
RESULTS: CSII group had significantly better HRQoL according to both child self-report and parent proxy-report. Youths with CSII reported better physical, emotional, and school-related functioning, and had less diabetes-related fear and symptoms than the MDI group. There were no significant differences in body mass index z-scores, insulin doses, HbA1c, and VO2max between the groups. HRQoL was predicted by the CSII therapy (β = -0.220; p = .000) and the VO2max (β = 0.386; p = .000), other clinical and anthropometric parameters had no effect; the HbA1c was predicted only by VO2max (β = -0.353; p = .000).
CONCLUSIONS: Diabetic youths treated with CSII therapy have better HRQoL than those treated with MDI. There are no differences between the investigated groups in anthropometric data, glycated hemoglobin, and physical fitness. Moreover, good physical fitness has an important role in achieving better metabolic control and HRQoL, which underlines the importance of regular aerobic exercise in the treatment and care of type 1 diabetes in childhood.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23270655     DOI: 10.1017/S0266462312000797

Source DB:  PubMed          Journal:  Int J Technol Assess Health Care        ISSN: 0266-4623            Impact factor:   2.188


  5 in total

Review 1.  [Insulin pump therapy in children, adolescents and adults].

Authors:  Marietta Stadler; Sandra Zlamal-Fortunat; Ingrid Schütz-Fuhrmann; Birgit Rami-Merhar; Elke Fröhlich-Reiterer; Sabine Hofer; Julia Mader; Michael Resl; Alexandra Kautzky-Willer; Raimund Weitgasser; Rudolf Prager; Martin Bischof
Journal:  Wien Klin Wochenschr       Date:  2016-04       Impact factor: 1.704

Review 2.  Continuous subcutaneous insulin infusion in diabetes: patient populations, safety, efficacy, and pharmacoeconomics.

Authors:  Paolo Pozzilli; Tadej Battelino; Thomas Danne; Roman Hovorka; Przemyslawa Jarosz-Chobot; Eric Renard
Journal:  Diabetes Metab Res Rev       Date:  2015-06-22       Impact factor: 4.876

3.  A determination of the quality of life of children and adolescents with type 1 diabetes and their parents.

Authors:  Nurcan Özyazıcıoğlu; Elif Ünsal Avdal; Halil Sağlam
Journal:  Int J Nurs Sci       Date:  2017-02-04

4.  Health-related quality of life in paediatric patients with Type 1 diabetes mellitus using insulin infusion systems. A systematic review and meta-analysis.

Authors:  Bastian Rosner; Andres Roman-Urrestarazu
Journal:  PLoS One       Date:  2019-06-25       Impact factor: 3.240

Review 5.  New and Emerging Technologies in Type 1 Diabetes.

Authors:  Jordan S Sherwood; Steven J Russell; Melissa S Putman
Journal:  Endocrinol Metab Clin North Am       Date:  2020-10-14       Impact factor: 4.741

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.